What are considerations for inhaled nitric oxide (iNO) in centers that do not have immediate availability of extracorporeal membrane oxygenation (ECMO) for treatment of persistent pulmonary hypertension of the newborn (PPHN)?

Updated: Sep 03, 2019
  • Author: Kate A Tauber, MD; Chief Editor: Howard S Weber, MD, FSCAI  more...
  • Print
Answer

Answer

In centers that do not have immediate availability of ECMO support, use of iNO must be approached with caution. Since iNO cannot be abruptly discontinued, transport with iNO is usually needed if a subsequent referral for ECMO is necessary. This capability should be determined in collaboration with the ECMO center before treatment is started. The use of iNO with HFV creates particular problems for transport, and this should be considered before these therapies are combined in a non-ECMO center. [46]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!